Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 13/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.61 |
| ▸ | RAF1 | P04049 | 5/20 | 0.56 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606327 | 0.80 | MAPK13 (0.71) | GCGRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6471005 | 0.77 | MAPK13 (1.00) | GCGRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2649730 | 0.77 | MAPK13 (1.00) | GCGRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2647350 | 0.74 | GCGR (1.00) | GCGRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8309758 | 0.74 | MAPK13 (0.75) | GCGRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2648873 | 0.73 | MAPK13 (0.73) | GCGRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL19869000 | 0.73 | MAPK13 (0.73) | GCGRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8309945 | 0.73 | MAPK14 (0.73) | GCGRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL12673346 | 0.72 | GFER (0.39) | — | |
| SCHEMBL5921859 | 0.72 | MAPK13 (1.00) | GCGRMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0959886-A4 | TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS | MERCK & CO INC (US) | 2001-05-02 | — | — | EP | claimed |
| EP-0959886-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS | Merck & Co., Inc. (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998022109-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0959886-A4 | TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS | MERCK & CO INC (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0959886-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS | Merck & Co., Inc. (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5880139-A | TREATING DIABETES, OBESITY, HYPERTENSION, CACHEXIA | MERCK & CO., INC. (US) | 1999-03-09 | — | — | US | disclosed |
| WO-1998022109-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | disclosed |